SOMA Research

What Is Semax? A Research Guide to the ACTH(4-7) Heptapeptide

Semax is a synthetic heptapeptide built from a fragment of adrenocorticotropic hormone with a three-residue tail added to the C-terminus. Its design answers a specific question: can you keep the part of a hormone that has signalling activity in the nervous system while removing the part that has hormonal activity, and then stop the result from being degraded immediately? This guide covers the structure, what the added tripeptide does, the published research context, and laboratory handling.

SOMA Research supplies Semax for laboratory research use only. It is not a drug, supplement, food or cosmetic, is not approved by the FDA for any use, and is not intended for human or veterinary consumption.

What Semax is

  • Sequence: Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP)
  • CAS number: 80714-61-0
  • Molecular formula: C37H51N9O10S
  • Molecular weight: approximately 813.9 g/mol
  • Length: 7 amino acids
  • Appearance: white lyophilised powder

The first four residues — Met-Glu-His-Phe — are ACTH(4-7), a fragment of adrenocorticotropic hormone. The last three — Pro-Gly-Pro — are not part of ACTH at all. They were added.

Two design decisions, both deliberate

Taking only ACTH(4-7). Full-length ACTH is a 39-residue hormone whose principal endocrine function depends on its N-terminal region binding melanocortin receptors. The 4-7 fragment does not carry that corticotropic activity. Isolating it was a way to separate the neuroactive properties attributed to ACTH fragments in the literature from the hormonal axis, so that a compound could be studied in neurological models without engaging the adrenal response.

Adding Pro-Gly-Pro. A four-residue peptide in a biological matrix is degraded very quickly by exopeptidases. The Pro-Gly-Pro extension is a stabilising motif: proline residues at and near the terminus hinder exopeptidase access, and the glycine between them provides the backbone flexibility the motif needs. The result is a peptide with meaningfully greater resistance to degradation than the bare fragment.

The same motif appears in Selank, which pairs Pro-Gly-Pro with a tuftsin fragment. If both compounds are in a comparative panel, note that they share the stabilising tail and differ in the active fragment — which makes the tail a constant rather than a variable in any comparison between them. SOMA lists Selank separately.

Published research context

Semax was developed in Russia and the majority of its literature is Russian-language or Russian-origin. This is relevant context when assessing the evidence base: much of the primary work is less accessible to English-language review and less frequently replicated by independent groups elsewhere. The principal reported threads are:

  • Neurotrophin expression. Rodent studies reporting changes in brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression, particularly in hippocampal tissue.
  • Transcriptional profiling. Gene expression studies in rodent brain tissue following administration.
  • Monoaminergic systems. Work examining interactions with dopaminergic and serotonergic signalling in animal models.
  • Ischaemia models. A body of rodent work in cerebral ischaemia models.

Semax holds a regulatory registration in the Russian Federation for certain indications. That registration is specific to that jurisdiction and to a pharmaceutical product manufactured for it. It is not an FDA approval, it does not extend to research-grade material, and it should not be read as an efficacy finding accepted by regulators elsewhere. Research-grade Semax carries no approval in any jurisdiction.

Semax variants

Several modified forms circulate and are not interchangeable with the base peptide:

  • N-Acetyl Semax. Acetylation of the N-terminal methionine, a modification intended to further slow N-terminal degradation.
  • N-Acetyl Semax amidate. Acetylated at the N-terminus and amidated at the C-terminus, blocking both ends.

Each modification changes the molecular weight, so a CoA for a variant will report a different mass than 813.9 g/mol. If published results are being compared, check which form each study used — the literature does not always make the distinction clearly, and a molarity calculation performed with the wrong mass will be wrong by the mass of the modification.

Analytical characterisation

  • HPLC purity. Reversed-phase separation of the target from deletion sequences and synthesis-related impurities, reported as a percentage of total peak area.
  • Mass spectrometry. Identity confirmation against approximately 813.9 g/mol for the base peptide.
  • A point specific to this sequence: the N-terminal methionine is a sulphur-containing residue and methionine is readily oxidised to the sulphoxide. That oxidation adds 16 Da and produces a distinct, earlier-eluting peak on a reversed-phase trace. It is one of the more common degradation products for this peptide and a reason to take both the storage conditions and the chromatographic trace seriously rather than only the headline purity number.

Every SOMA lot is tested by third-party laboratories using HPLC and mass spectrometry, with measured figures published per lot in our CoA library. The Certificate of Analysis guide explains how to read a trace and which combinations of results should prompt a question.

Handling and storage

  • Lyophilised powder: -20°C, protected from light.
  • Reconstituted stock: 2–8°C, aliquoted, used within approximately 30 days.
  • Minimise oxygen exposure. Because of the N-terminal methionine, prolonged exposure of solutions to air promotes sulphoxide formation. Keep vials closed, limit headspace in stored aliquots, and avoid leaving working solutions standing.
  • Avoid oxidising agents in buffers, for the same reason.
  • Avoid freeze-thaw cycling.

The general procedure and the concentration arithmetic are in our reconstitution guide.

Research use only

Research-grade Semax is supplied for laboratory use by qualified researchers and institutions. It is not manufactured to pharmaceutical standards, has not been approved by the FDA for any use, and must not be used in or on humans or animals. Nothing in this guide is medical advice or a representation that the compound is safe or effective for any purpose.